Insulin-like Growth Factor-Binding Protein-6 (IGFBP-6)
- SKU:
- E112
- Bulk Pricing:
-
- Buy 5 - 20 and get 5% off
- Buy 21 - 30 and get 10% off
- Buy 31 - 50 and get 15% off
- Buy 51 or more – call for best pricing
The cookie settings on this website are set to 'allow all cookies' to give you the very best experience. Please click Accept Cookies to continue to use the site.
Enzyme-linked immunoassay (ELISA) for the determination of Insulin-like Growth Factor 6 (IGFBP-6) in serum, plasma, cell culture medium, and other body fluids. For research use only, not for use in diagnostic procedures.<br><br>
The Insulin-like Growth Factor 6 (IGFBP-6) is part of the IGF-System which consists of several binding proteins (1-6) and IGF-I and –II. The Insulin-like Growth Factors are involved in the control of human growth and regulated themselves by their binding proteins. The IGFBPs show high amino acid sequence homology, they have conserved N- and C-terminal domains which are involved in IGF-binding. In contrast the central linker region is highly variable. This region is not directly involved in IGF-binding but influences stability and localization of the IGFBP / IGF complex and can be modified by glycosylation and phosphorylation.<br><br>
IGFBP-6 a protein of 213 amino acids and about 34 kDa is somewhat special because of only three disulphide bridges in the C-terminal domain, resulting in a significantly higher affinity (50fold) for IGF-II than IGF-I. Further IGFBP-6 can be O-glycosylated and is cleaved by cathepsin-D-like acid protease, neutral serine protease as well as MMP-2/-7/-9/-12.<br><br>
Main proposed function of IGFBP-6 is the regulation of the biological availability of IGF-II and thereby it influences cell proliferation, differentiation, migration and survival. Further IGF-independent as well as intra- and nuclear actions of IGFBP-6 are discussed. IGF-independent actions might be transmitted by prohibitin-2 as a potential cell surface receptor. Physiologically IGFBP-6 might be involved in senescence, angiogenesis and cancer. But a clear clinical indication for measurement of plasma IGFBP-6 needs to be determined (Bach, 2015).
Enzyme-linked immunoassay (ELISA) for the determination of Insulin-like Growth Factor 6 (IGFBP-6) in serum, plasma, cell culture medium, and other body fluids. For research use only, not for use in diagnostic procedures.<br><br>
The Insulin-like Growth Factor 6 (IGFBP-6) is part of the IGF-System which consists of several binding proteins (1-6) and IGF-I and –II. The Insulin-like Growth Factors are involved in the control of human growth and regulated themselves by their binding proteins. The IGFBPs show high amino acid sequence homology, they have conserved N- and C-terminal domains which are involved in IGF-binding. In contrast the central linker region is highly variable. This region is not directly involved in IGF-binding but influences stability and localization of the IGFBP / IGF complex and can be modified by glycosylation and phosphorylation.<br><br>
IGFBP-6 a protein of 213 amino acids and about 34 kDa is somewhat special because of only three disulphide bridges in the C-terminal domain, resulting in a significantly higher affinity (50fold) for IGF-II than IGF-I. Further IGFBP-6 can be O-glycosylated and is cleaved by cathepsin-D-like acid protease, neutral serine protease as well as MMP-2/-7/-9/-12.<br><br>
Main proposed function of IGFBP-6 is the regulation of the biological availability of IGF-II and thereby it influences cell proliferation, differentiation, migration and survival. Further IGF-independent as well as intra- and nuclear actions of IGFBP-6 are discussed. IGF-independent actions might be transmitted by prohibitin-2 as a potential cell surface receptor. Physiologically IGFBP-6 might be involved in senescence, angiogenesis and cancer. But a clear clinical indication for measurement of plasma IGFBP-6 needs to be determined (Bach, 2015).